Multicenter phase 3 trial of suvemcitug plus chemotherapy for platinum-resistant recurrent ovarian cancer

Suvemcitug (BD0801) is a humanized rabbit monoclonal anti-VEGF antibody. In the phase 3 SCORES trial, at 55 tertiary-care centers in China, women with platinum-resistant ovarian cancer (PROC) that progressed within 6 months after completing platinum-based therapy were randomized 2:1 to receive suvemcitug (1.5 mg/kg) or placebo every two weeks, with chemotherapy (paclitaxel, topotecan, or pegylated liposomal doxorubicin). The primary endpoint was progression-free survival (PFS). Among 421 randomized participants, 49.4% were previously exposed to antiangiogenic agents and 49.9% were previously exposed to PARP inhibitors. Median progression-free survival was 5.5 and 2.7 months in the suvemcitug and placebo arms, respectively (HR 0.46; p<0.001), meeting the primary endpoint. Median overall survival (OS) was 15.3 versus 14.0 months, respectively (HR 0.77; p=0.03). The most common grade 3 or 4 treatment-emergent adverse events in the suvemcitug arm were decreased neutrophil and leukocyte counts; there were no sivemcitug-related grade 5 TEAEs. The authors conclude that addition of suvemcitug to chemotherapy significantly improved PFS and OS among women with PROC, with tolerable toxicities.